Perioperative Management of Renal Transplant Patients
Continue all immunosuppressive medications through the perioperative period without interruption, maintaining calcineurin inhibitor (CNI) levels in the therapeutic range with close monitoring. 1
Immunosuppression Management
Preoperative Period
Do not withhold immunosuppressive medications before surgery. The KDIGO guidelines explicitly recommend starting CNI (tacrolimus or cyclosporine) before or at the time of transplantation and continuing maintenance immunosuppression without interruption 1. For transplant recipients undergoing subsequent non-transplant surgery, this principle extends to maintaining their established immunosuppressive regimen.
- Tacrolimus or cyclosporine: Continue at current doses
- Mycophenolate or azathioprine: Continue without interruption
- Prednisone: Continue maintenance dose 1
The evidence from organ transplant patients supports continuing anti-rejection therapy without interruption at the time of surgery 2. Unlike the rheumatology guidelines that recommend withholding certain immunosuppressants in non-severe SLE patients, renal transplant recipients require continuous immunosuppression to prevent acute rejection, which can occur as early as 1 week post-transplant and remains a risk throughout the graft's life 1.
Intraoperative Considerations
Monitor for drug interactions between immunosuppressive agents and anesthetic medications 3:
- Patients receiving cyclosporine may require smaller doses of non-depolarizing muscle relaxants with prolonged recovery time 3
- Use agents independent of kidney function when possible (cisatracurium, atracurium) or those with reversal options (sugammadex) 3
- Avoid etomidate, which can suppress adrenal function in patients on chronic steroids
Maintain strict infection prevention protocols given the immunocompromised state 3.
Postoperative Period
Resume oral immunosuppression as soon as the patient can tolerate oral intake. If prolonged NPO status is anticipated:
- Convert to intravenous formulations when available
- Coordinate with transplant nephrology for alternative dosing strategies
- Never allow gaps in immunosuppressive coverage
CNI Monitoring Protocol
Measure CNI blood levels frequently in the perioperative period 1:
- Every other day during the immediate post-operative period until target levels are reached
- Whenever there is a change in medication or patient status that may affect blood levels
- Whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection
For tacrolimus: Monitor 12-hour trough (C0) levels 1
For cyclosporine: Monitor 12-hour trough (C0), 2-hour post-dose (C2), or abbreviated AUC 1
Fluid Management
Use balanced crystalloids for perioperative fluid therapy 4. Avoid hypervolemia while maintaining adequate perfusion to the transplanted kidney 5, 6.
- Goal-directed fluid therapy guided by dynamic hemodynamic parameters
- Avoid fluid overload, which is associated with adverse outcomes
- Consider early vasopressor support for vasodilatory hypotension rather than excessive fluid administration 5
Avoid synthetic colloids, which have shown harm signals in critically ill patients 4. Albumin should not be used routinely 4.
Cardiovascular Management
Assess cardiovascular status preoperatively, as transplant recipients often have significant cardiovascular comorbidity 7, 5:
- Evaluate for cardiac allograft vasculopathy in heart transplant recipients
- Recognize that transplanted kidneys are denervated and may not respond normally to autonomic stimuli
- Coordinate with the transplant team for major procedures requiring general or regional anesthesia 7
Renal Function Monitoring
Measure serum creatinine frequently 1:
- Daily for 7 days or until hospital discharge, whichever occurs sooner
- 2-3 times per week for weeks 2-4
- Weekly for months 2 and 3
Measure urine output 1:
- Every 1-2 hours for at least 24 hours after any surgical procedure
- Daily until graft function is stable
If graft dysfunction occurs, obtain kidney allograft biopsy to detect potentially reversible causes before initiating treatment 1.
Infection Prevention
Maintain heightened infection prevention measures 3:
- Active warming to prevent hypothermia, which increases infection rates 3
- Strict aseptic technique
- Consider antimicrobial prophylaxis per institutional protocols
- Monitor for signs of infection closely in the postoperative period
Anemia and Transfusion
Optimize hemoglobin preoperatively 8. Transfusion decisions should minimize the risk of HLA allosensitization and CMV infection 7:
- Use leukoreduced blood products
- Use CMV-negative blood products when possible
- Maintain restrictive transfusion thresholds unless specific indications exist
Critical Pitfalls to Avoid
- Never discontinue immunosuppression perioperatively - This is fundamentally different from rheumatologic disease management and risks acute rejection
- Do not assume normal renal function - Even well-functioning transplants may have reduced reserve
- Avoid nephrotoxic agents when possible (NSAIDs, aminoglycosides, contrast)
- Do not delay resumption of oral immunosuppression - Convert to IV if needed but maintain coverage
- Monitor CNI levels closely - Perioperative stress, medications, and NPO status can all affect levels
Multidisciplinary Coordination
Coordinate care with the transplant nephrology team for all major surgical procedures 7, 8. This includes:
- Preoperative risk assessment
- Immunosuppression management plan
- Postoperative monitoring strategy
- Early recognition and management of complications